| Pain Management |
1 |
1 |
| Hepatic Porphyria |
0 |
0.99 |
| Porphyria |
0 |
0.72 |
| Acute Intermittent Porphyria |
0 |
0.61 |
| Variegate Porphyria |
0 |
0.57 |
| Genomic Medicine |
0 |
0.33 |
| Genetic Testing |
0 |
0.26 |
| Abdominal Pain |
0 |
0.23 |
| Genetics |
0 |
0.23 |
| Liver |
0 |
0.18 |
| Hepatocellular Carcinoma |
0 |
0.17 |
| Liver Disease |
0 |
0.16 |
| Chronic Kidney Disease |
0 |
0.15 |
| Renal Failure |
0 |
0.15 |
| Abdomen |
0 |
0.14 |
| Intravenous |
0 |
0.14 |
| Pain |
0 |
0.14 |
| Preventive Screening |
0 |
0.14 |
| Facial Pain |
0 |
0.1 |
| Renal Disease |
0 |
0.1 |
| Arrhythmia |
0 |
0.09 |
| California |
0 |
0.09 |
| Hereditary Coproporphyria |
0 |
0.09 |
| Hypertension |
0 |
0.09 |
| Kidney |
0 |
0.09 |
| Pregnancy |
0 |
0.09 |
| Rare Diseases |
0 |
0.09 |
| Tachycardia |
0 |
0.09 |
| Tobacco Cessation |
0 |
0.08 |
| Tobacco Use |
0 |
0.08 |
| Constipation |
0 |
0.05 |
| Deep Venous Thrombosis |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Hyponatremia |
0 |
0.05 |
| Thromboembolism |
0 |
0.05 |
| Analgesia |
0 |
0.04 |
| Antiemetic |
0 |
0.04 |
| Board Certification |
0 |
0.04 |
| Cancer |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Face |
0 |
0.04 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.04 |
| Hypomagnesemia |
0 |
0.04 |
| Living Donor |
0 |
0.04 |
| Metabolism |
0 |
0.04 |
| Muscle |
0 |
0.04 |
| Nausea |
0 |
0.04 |
| Neuropathy |
0 |
0.04 |
| Off-Label Use |
0 |
0.04 |
| Peripherally Inserted Central Catheters |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |
| Refractory |
0 |
0.04 |
| Thrombophlebitis |
0 |
0.04 |
| Transplantation |
0 |
0.04 |
| Ultrasonography |
0 |
0.04 |
| Vein |
0 |
0.04 |
| Weakness |
0 |
0.04 |